Kalvista Pharmaceuticals Inc (KALV) is now in the Undervalued zone, suggesting that its current forward PS ratio of 11.93 is considered Undervalued compared with the five-year average of -3.85. The fair price of Kalvista Pharmaceuticals Inc (KALV) is between 27.29 to 51.99 according to relative valuation method. Compared to the current price of 16.06 USD , Kalvista Pharmaceuticals Inc By Undervalued By 41.14%.

Relative Value

Fair Zone

27.29-51.99

Current Price：16.06

41.14%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Kalvista Pharmaceuticals Inc (KALV) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Kalvista Pharmaceuticals Inc (KALV) has a current Price-to-Book (P/B) ratio of 19.08. Compared to its 3-year average P/B ratio of 5.18, the current P/B ratio is approximately 268.19% higher. Relative to its 5-year average P/B ratio of 3.96, the current P/B ratio is about 381.96% higher. Kalvista Pharmaceuticals Inc (KALV) has a Forward Free Cash Flow (FCF) yield of approximately -21.48%. Compared to its 3-year average FCF yield of -22.74%, the current FCF yield is approximately -5.52% lower. Relative to its 5-year average FCF yield of -22.93%, the current FCF yield is about -6.32% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for KALV competitors is 59.06, providing a benchmark for relative valuation. Kalvista Pharmaceuticals Inc Corp (KALV.O) exhibits a P/S ratio of 11.93, which is -79.8% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of KALV increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of KALV in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is KALV currently overvalued or undervalued?

Kalvista Pharmaceuticals Inc (KALV) is now in the Undervalued zone, suggesting that its current forward PS ratio of 11.93 is considered Undervalued compared with the five-year average of -3.85. The fair price of Kalvista Pharmaceuticals Inc (KALV) is between 27.29 to 51.99 according to relative valuation method. Compared to the current price of 16.06 USD, Kalvista Pharmaceuticals Inc is Undervalued By 41.14%.

What is Kalvista Pharmaceuticals Inc (KALV) fair value?

KALV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Kalvista Pharmaceuticals Inc (KALV) is between 27.29 to 51.99 according to relative valuation method.

How does KALV's valuation metrics compare to the industry average?

The average P/S ratio for KALV's competitors is 59.06, providing a benchmark for relative valuation. Kalvista Pharmaceuticals Inc Corp (KALV) exhibits a P/S ratio of 11.93, which is -79.80% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Kalvista Pharmaceuticals Inc (KALV) as of Mar 03 2026?

As of Mar 03 2026, Kalvista Pharmaceuticals Inc (KALV) has a P/B ratio of 19.08. This indicates that the market values KALV at 19.08 times its book value.

What is the current FCF Yield for Kalvista Pharmaceuticals Inc (KALV) as of Mar 03 2026?

As of Mar 03 2026, Kalvista Pharmaceuticals Inc (KALV) has a FCF Yield of -21.48%. This means that for every dollar of Kalvista Pharmaceuticals Inc's market capitalization, the company generates -21.48 cents in free cash flow.

What is the current Forward P/E ratio for Kalvista Pharmaceuticals Inc (KALV) as of Mar 03 2026?

As of Mar 03 2026, Kalvista Pharmaceuticals Inc (KALV) has a Forward P/E ratio of -4.13. This means the market is willing to pay $-4.13 for every dollar of Kalvista Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Kalvista Pharmaceuticals Inc (KALV) as of Mar 03 2026?

As of Mar 03 2026, Kalvista Pharmaceuticals Inc (KALV) has a Forward P/S ratio of 11.93. This means the market is valuing KALV at $11.93 for every dollar of expected revenue over the next 12 months.

KALV Valuation